Zacks Research Brokers Reduce Earnings Estimates for TEVA

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities researchers at Zacks Research cut their Q3 2025 earnings estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.69 per share for the quarter, down from their previous estimate of $0.71. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.40 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS, FY2026 earnings at $2.60 EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $2.80 EPS.

Several other equities research analysts have also commented on the stock. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price objective on the stock. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $24.50.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $17.20 on Monday. The firm has a market capitalization of $19.50 billion, a P/E ratio of -11.86, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The company’s fifty day moving average is $15.58 and its two-hundred day moving average is $17.37. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business’s revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE lifted its holdings in Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock valued at $166,000 after purchasing an additional 656 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after purchasing an additional 699 shares in the last quarter. Bfsg LLC lifted its holdings in Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company’s stock valued at $168,000 after purchasing an additional 790 shares in the last quarter. Townsquare Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.